Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.808
EU - Europa 4.556
AS - Asia 2.540
SA - Sud America 161
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 3
Totale 19.090
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.527
SG - Singapore 1.034
IT - Italia 765
SE - Svezia 750
IE - Irlanda 728
CN - Cina 714
DE - Germania 540
RU - Federazione Russa 492
HK - Hong Kong 439
UA - Ucraina 426
GB - Regno Unito 232
CA - Canada 229
FI - Finlandia 158
BR - Brasile 144
AT - Austria 142
VN - Vietnam 99
DK - Danimarca 82
TR - Turchia 76
FR - Francia 62
ID - Indonesia 57
IN - India 49
RO - Romania 45
BE - Belgio 40
MX - Messico 31
NL - Olanda 27
PL - Polonia 15
IR - Iran 14
CZ - Repubblica Ceca 12
EU - Europa 9
JP - Giappone 9
CH - Svizzera 7
IQ - Iraq 6
CL - Cile 5
ES - Italia 5
HN - Honduras 5
PA - Panama 5
AR - Argentina 4
AZ - Azerbaigian 4
BG - Bulgaria 4
BZ - Belize 4
EG - Egitto 4
PT - Portogallo 4
BD - Bangladesh 3
CR - Costa Rica 3
GR - Grecia 3
IL - Israele 3
JO - Giordania 3
KR - Corea 3
MY - Malesia 3
NP - Nepal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
BY - Bielorussia 2
EC - Ecuador 2
EE - Estonia 2
KH - Cambogia 2
LU - Lussemburgo 2
MK - Macedonia 2
ML - Mali 2
PE - Perù 2
PH - Filippine 2
SA - Arabia Saudita 2
TH - Thailandia 2
TW - Taiwan 2
BO - Bolivia 1
BS - Bahamas 1
CO - Colombia 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
IM - Isola di Man 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PS - Palestinian Territory 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
UY - Uruguay 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 19.090
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.412
Woodbridge 1.344
Fairfield 1.231
Houston 1.015
Chandler 745
Dublin 713
Ashburn 651
Singapore 641
Jacksonville 565
Wilmington 538
Seattle 469
Hong Kong 437
Cambridge 435
Frankfurt am Main 390
Dearborn 319
New York 306
Princeton 279
Milan 229
Santa Clara 178
Nanjing 148
Altamura 133
Lawrence 133
Vienna 119
Lachine 110
Shanghai 105
Dong Ket 83
San Diego 72
Beijing 68
Los Angeles 56
Ottawa 56
Andover 51
Boardman 50
Fremont 50
Jakarta 49
Nanchang 46
Helsinki 44
Galati 43
Hebei 41
Brussels 40
Shenyang 38
London 33
Toronto 31
Norwalk 28
Falls Church 25
Nuremberg 24
Florence 22
Guangzhou 20
Hangzhou 20
Tianjin 19
Changsha 18
Cuauhtémoc 18
Edmonton 17
Buffalo 16
Munich 16
Pune 16
Kunming 15
Council Bluffs 14
Jiaxing 14
Mountain View 14
São Paulo 14
Dallas 13
Rome 13
Chicago 11
Jinan 11
Kiev 10
Loreto 10
Zhengzhou 10
Amsterdam 9
Detroit 9
Ningbo 9
San Mateo 9
Washington 9
Rio de Janeiro 8
Turin 8
Bari 7
Brescia 7
Clearwater 7
Lissone 7
Redmond 7
Romola 7
Auburn Hills 6
Brno 6
Kilburn 6
Monza 6
San Giuliano Milanese 6
Tokyo 6
Vercelli 6
Hanoi 5
Laurel 5
Phoenix 5
San Francisco 5
Santiago 5
Taizhou 5
Tegucigalpa 5
Baku 4
Belize City 4
Carate Brianza 4
Enterprise 4
Hounslow 4
Huizen 4
Totale 14.108
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 298
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 264
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 241
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 233
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 227
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 226
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 224
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 223
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 216
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 209
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 208
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 208
HIV testing: A must for patients with inflammatory bowel disease 206
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 206
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 200
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 200
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 192
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 191
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 190
Brachial and central blood pressure in HIV-infected subjects 187
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 187
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 185
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 183
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 180
Focal bone lesions in hiv-positive patient treated with tenofovir 179
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 179
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 178
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 176
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 175
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 174
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 173
Unmasking tuberculosis in the era of antiretroviral treatment 171
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 169
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 169
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 169
Strategies to limit immune-activation in HIV patients 169
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 168
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 168
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 167
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 167
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 167
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 161
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 160
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 159
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 158
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 155
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 155
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 154
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 153
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 153
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 153
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 151
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 151
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 150
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 150
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 149
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 146
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 146
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 145
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 145
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 142
Re: The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options 142
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 140
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 139
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 138
Antimicrobial therapy duration: A major matter in the management of severe infections 138
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 138
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 137
Inflammatory cytokines drive CD4+ t-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease 136
Beyond the gut bacterial microbiota: The gut virome 136
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 136
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 135
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 134
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 131
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 131
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 130
To the editor 130
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 130
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 127
Immunity to human immunodeficiency virus (HIV) infection 126
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme 125
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 124
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 123
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics 123
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 122
The immunomodulatory nutritional intervention NR100157 reduced CD4 + T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study) 120
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 120
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: Results from the Italian MASTER Cohort 120
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 118
Letter: Antibiotic dose adjustment in patients with advanced liver disease 116
Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and Beijing/W family of Mycobacterium tuberculosis 115
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 115
Exogenous reinfection of tuberculosis in a low-burden area 115
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 115
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 115
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 114
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 114
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 114
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 113
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 111
Totale 15.944
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.585
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.585
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020610 0 0 0 0 0 0 0 0 0 235 271 104
2020/20212.067 151 222 233 223 145 119 184 151 162 212 89 176
2021/20221.509 40 103 212 146 73 135 61 124 72 118 116 309
2022/20232.909 369 803 233 291 188 471 31 167 210 28 72 46
2023/20242.086 43 72 97 81 283 552 427 80 145 49 35 222
2024/20252.930 285 525 358 211 390 156 241 170 571 23 0 0
Totale 20.036